253 related articles for article (PubMed ID: 19355801)
1. Challenges for managing overactive bladder and guidance for patient support.
Schabert VF; Bavendam T; Goldberg EL; Trocio JN; Brubaker L
Am J Manag Care; 2009 Mar; 15(4 Suppl):S118-22. PubMed ID: 19355801
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported reasons for discontinuing overactive bladder medication.
Benner JS; Nichol MB; Rovner ES; Jumadilova Z; Alvir J; Hussein M; Fanning K; Trocio JN; Brubaker L
BJU Int; 2010 May; 105(9):1276-82. PubMed ID: 19912188
[TBL] [Abstract][Full Text] [Related]
3. Predictors of discontinuing overactive bladder medications.
Brubaker L; Fanning K; Goldberg EL; Benner JS; Trocio JN; Bavendam T; Jumadilova Z
BJU Int; 2010 May; 105(9):1283-90. PubMed ID: 19912189
[TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
5. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
6. Impact of overactive bladder on women in the United States: results of a national survey.
Dmochowski RR; Newman DK
Curr Med Res Opin; 2007 Jan; 23(1):65-76. PubMed ID: 17257467
[TBL] [Abstract][Full Text] [Related]
7. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.
Andersson KE; Sarawate C; Kahler KH; Stanley EL; Kulkarni AS
BJU Int; 2010 Jul; 106(2):268-74. PubMed ID: 19922546
[TBL] [Abstract][Full Text] [Related]
9. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
Bolge SC; McDonnell DD; Chen A; Wan GJ
Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
[TBL] [Abstract][Full Text] [Related]
10. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update.
Athanasopoulos A; Chapple C; Fowler C; Gratzke C; Kaplan S; Stief C; Tubaro A
Eur Urol; 2011 Jul; 60(1):94-105. PubMed ID: 21497434
[TBL] [Abstract][Full Text] [Related]
11. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
12. Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.
Toglia MR; Serels SR; Laramée C; Karram MM; Nandy IM; Andoh M; Seifeldin R; Forero-Schwanhaeuser S
Postgrad Med; 2009 Sep; 121(5):151-8. PubMed ID: 19820284
[TBL] [Abstract][Full Text] [Related]
13. Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study).
Choo MS; Doo CK; Lee KS
Int J Clin Pract; 2008 Feb; 62(2):191-6. PubMed ID: 18067558
[TBL] [Abstract][Full Text] [Related]
14. Medication nonadherence secondary to drug-induced memory loss.
Nye AM; Clinard VB; Barnes CL
Consult Pharm; 2010 Feb; 25(2):117-21. PubMed ID: 20211824
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
16. A review of adherence to drug therapy in patients with overactive bladder.
Basra RK; Wagg A; Chapple C; Cardozo L; Castro-Diaz D; Pons ME; Kirby M; Milsom I; Vierhout M; Van Kerrebroeck P; Kelleher C
BJU Int; 2008 Sep; 102(7):774-9. PubMed ID: 18616691
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
Ko Y; Malone DC; Armstrong EP
Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
[TBL] [Abstract][Full Text] [Related]
18. Comparative persistence and adherence to overactive bladder medications in patients with and without diabetes.
Johnston S; Janning SW; Haas GP; Wilson KL; Smith DM; Reckard G; Quan SP; Bukofzer S
Int J Clin Pract; 2012 Nov; 66(11):1042-51. PubMed ID: 23067028
[TBL] [Abstract][Full Text] [Related]
19. Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.
Kay GG; Granville LJ
Clin Ther; 2005 Jan; 27(1):127-38; quiz 139-40. PubMed ID: 15763613
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]